Norcantharidin alleviates cyclophosphamide-induced immunosuppression via circBCL2L1/miR-30c-3-3p/TRAF6 axis

Cyclophosphamide is a widely used antitumor drug, with induced adverse effects, such as intestinal mucosal injury and immunosuppression. Norcantharidin possesses anticancer activity through enhancement of immunity. We investigated the role norcantharidin in cyclophosphamide-induced Mice were treated cyclophosphamide, exposed to norcantharidin. Enzyme-linked-immunosorbent serologic assay was performed assess levels immunoglobulin cytokines serum, splenic T lymphocytes analyzed by immunohistochemistry. Incubation increased serum G (IgG), interleukin (IL)-12, interferon-gamma (IFN-?), IL-6, enhanced percentage CD4+ CD8+ mice. Expression circBCL2L1 down-regulated spleen mice, while up-regulated incuba-tion. attenuated up-regulation miR-30c-3-3p down-regulation tumor necrosis factor (TNF) receptor-associated 6 (TRAF6) Over-expression cytokines, Moreover, over-expression TRAF6 mice miR-30c-3-3p. Knockdown norcantharidin-induced increase IgG, IL-12, IFN-?, exhibited protective effect against immunosuppression regulation circBCL2L1/miR-30c-3-3p/TRAF6 axis.